- Home
- COLL vs ULCC Comparison
COLL vs ULCC Comparison
Compare COLL & ULCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COLL
- ULCC
- Stock Information
- Founded
- COLL 2002
- ULCC 1994
- Country
- COLL United States
- ULCC United States
- Employees
- COLL N/A
- ULCC N/A
- Industry
- COLL Biotechnology: Pharmaceutical Preparations
- ULCC Air Freight/Delivery Services
- Sector
- COLL Health Care
- ULCC Consumer Discretionary
- Exchange
- COLL Nasdaq
- ULCC Nasdaq
- Market Cap
- COLL 958.8M
- ULCC 1.1B
- IPO Year
- COLL 2015
- ULCC 2021
- Fundamental
- Price
- COLL $38.32
- ULCC $5.18
- Analyst Decision
- COLL Strong Buy
- ULCC Hold
- Analyst Count
- COLL 4
- ULCC 10
- Target Price
- COLL $44.25
- ULCC $5.17
- AVG Volume (30 Days)
- COLL 427.8K
- ULCC 5.1M
- Earning Date
- COLL 08-07-2025
- ULCC 10-28-2025
- Dividend Yield
- COLL N/A
- ULCC N/A
- EPS Growth
- COLL N/A
- ULCC N/A
- EPS
- COLL 1.06
- ULCC N/A
- Revenue
- COLL $707,007,000.00
- ULCC $3,778,000,000.00
- Revenue This Year
- COLL $22.23
- ULCC $1.48
- Revenue Next Year
- COLL $2.78
- ULCC $13.13
- P/E Ratio
- COLL $36.58
- ULCC N/A
- Revenue Growth
- COLL 22.61
- ULCC 4.60
- 52 Week Low
- COLL $23.23
- ULCC $2.89
- 52 Week High
- COLL $42.29
- ULCC $10.26
- Technical
- Relative Strength Index (RSI)
- COLL 59.51
- ULCC 59.72
- Support Level
- COLL $38.00
- ULCC $5.09
- Resistance Level
- COLL $39.78
- ULCC $6.05
- Average True Range (ATR)
- COLL 0.97
- ULCC 0.37
- MACD
- COLL -0.18
- ULCC 0.08
- Stochastic Oscillator
- COLL 38.72
- ULCC 55.98
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About ULCC Frontier Group Holdings Inc.
Frontier Group Holdings Inc is an ultra-low-cost carrier whose business is focused on Low Fares Done Right. The company owns a fleet of 120 Airbus single-aisle aircraft, consisting of 13 A320ceos, 82 A320neos, 21 A321ceos and 4 A321neos. The use of these aircraft, their seating configuration, weight-saving tactics, and baggage process have all contributed to the ability to continue to be the fuel-efficient of all the U.S. The Company is managed as a single business unit that provides air transportation for passengers. Majority of revenue is from Domestic flight follow by International.